CEO of the Serum Institute of India Adar Poonawalla said pharmaceutical firms weren't ramping up their production capacity swiftly enough to adequately innoculate the world's population before the end of 2024, in an interview with the Financial Times (FT).
Roughly five months after top USA health officials coalesced around the idea of a public-private effort to accelerate the development, manufacturing, and distribution of Covid-19 vaccines, therapeutics, and diagnostics, an answer to that question remains out of reach.
Besides, the drug regulating body of the country has told the Serum Institute to take extra care during screening, provide additional information in informed consent, and closely monitor participants for any adverse events during follow-up of the study. They said that they will be following the instructions provided by the DCGI. In addition to this, they confirmed that the pause will continue till AstraZeneca restarts the trials. The late-stage trial involves around 30,000 participants in the US, UK, Brazil, and South Africa.
SIIPL is expected to manufacture 1 billion doses of the vaccine candidate in 2021.
The human trials in the United Kingdom resumed few days after getting paused after a participant reported illness.
The DCGI has revoked its earlier order of suspending recruitment of any new volunteer for the Phase 2/3 clinical trial.
Global pharma major AstraZeneca announced on Tuesday that the clinical trials will be temporarily halted. This will be crucial to ensure safety and maintain the integrity of the trials.
Governments around the world are desperate for a vaccine to help end the pandemic, which has caused more than 900,000 deaths and global economic turmoil.
The comments come after the COVID-19 vaccine trials of rival AstraZeneca Plc were put on hold worldwide last week after a severe side effect was reported in a volunteer in Britain.
When this happened late last week, Poonawala tweeted, "a$3 s I'd mentioned earlier, we should not jump to conclusions until the trials are fully concluded".